FDA expands Bravecto Quantum label for two additional dog ticks
The FDA has expanded the label for Merck Animal Health’s Bravecto Quantum, adding 12-month treatment and control claims in dogs for two more tick species: the Asian longhorned tick (Haemaphysalis longicornis) and the Gulf Coast tick (Amblyomma maculatum). Merck announced the approval on March 18, 2026. Bravecto Quantum, a veterinarian-administered extended-release fluralaner injection, was originally approved on July 10, 2025, as the first FDA-approved flea and tick product for dogs offering 8 to 12 months of protection, depending on tick species. The product’s existing label already covered adult fleas and flea infestations, plus black-legged ticks, American dog ticks, brown dog ticks, and lone star ticks, with lone star tick protection limited to 8 months. It is labeled for dogs 6 months of age and older and is available only through licensed veterinarians. (merck-animal-health.com, fda.gov)
Why it matters: For veterinary professionals, the expanded label gives clinics a broader once-yearly parasite control option in areas where Asian longhorned and Gulf Coast ticks are relevant concerns. That may simplify prevention conversations with pet parents and improve adherence for dogs that struggle with monthly dosing, while still requiring species-specific counseling because Bravecto Quantum does not provide a uniform 12 months of protection against every tick. FDA has also emphasized that the injection must be prescribed by a licensed veterinarian, in part because clinicians need to determine whether an 8- or 12-month interval is appropriate and discuss isoxazoline-associated neurologic adverse event warnings where relevant. (fda.gov, pharmashots.com)
What to watch: Watch for how quickly practices in tick-endemic regions incorporate the expanded label into protocols, and whether Merck further refines its marketing after a recent BBB National Advertising Division challenge over year-round tick protection claims. NAD said some language was acceptable, including the general statement that Bravecto Quantum is “a safe, effective way to protect dogs year-round,” but recommended changes or clearer disclosures when ads tied a single dose to a full year of protection without prominently noting the 8-month lone star tick interval. Merck said it would appeal at least part of the decision. (bbbprograms.org, todaysveterinarybusiness.com)